摘要
目的探讨口服培菲康对肝硬化患者肠道通透性和血浆内毒素水平的影响。方法将68例肝硬化患者随机分为对照组和培菲康组。对照组患者给予常规保肝、利尿和对症支持治疗;培菲康组患者在此基础上口服三联活菌胶囊(商品名:培菲康)0.42g/次,3次/d,疗程均为4周。分别在治疗前后观察两组患者肝功能、血浆二胺氧化酶(DAO)和内毒素水平的变化。结果两组患者治疗前肝功能、血浆DAO和内毒素水平比较均无明显统计学差异(P>0.05)。治疗4周后,两组患者肝功能(ALT、AST)、血浆DAO和内毒素水平均较治疗前明显下降(P<0.05或P<0.01),且培菲康组下降的幅度较对照组更明显(P<0.05)。结论口服培菲康可显著降低肠道通透性,改善肠黏膜屏障功能,从而降低血浆内毒素的水平,改善肝脏的功能,对肝硬化有辅助治疗作用。
Objective To study the effect of Bifico on intestinal permeability and plasma endotoxin in liver cirrhotic patients. Methods Sixty eight patients of liver cirrhosis were randomly divided into control group and Bifico group. The patients in treatment group were treated with 0.42g Bifid Triple Viable Capsule （ trade name, Bifico ） thrice a day combined with routine treatment including diuretic and symptomatic and supportive treatment. And those in control group were treated with routine treatment only. All patients were treated with a course of 4 weeks. Before and after treatment, two groups were respectively observed on liver function, plasma diamine oxidase （ DAO ） and endotoxin levels. Results There were no differences between two groups in liver function （ ALT, AST ）, plasma DAO and endotoxin levels before treatment （P 〉 0.05 ）. After 4 weeks treatment, all patients＇ liver function （ALT, AST ）, plasma DAO and endotoxin were significantly decreased than before treatment （P 〈 0.05 or P 〈 0.01 ）, and the decreased level in Bifico group was more significant than the control group （P 〈 0.05 ）. Conclusion Oral Bifico can significantly reduce intestinal permeability, improve intestinal mucosal barrier function, reduce plasma endotoxin levels and improve liver function, thereby it is a adjuvant therapy for liver cirrhotic patients.
出处
《中国现代医生》
2011年第20期79-80,88,共3页
China Modern Doctor
基金
浙江省台州市路桥区科技局课题(编号:2008C012)
关键词
肝硬化
培菲康
肝功能
肠道通透性
内毒素
Liver cirrhosis
Bifico
Liver function
Intestinal permeability
Endotoxin
